This inventor holds 1 USPTO granted patent. Top assignee: Sanofi-A Ventis Deutschland Gmbh. Active years: 2008.
Company Filing History:
Years Active: 2008
Title: Armin Ensser: Innovator in Immunomodulating Semaphorins
Introduction
Armin Ensser is a notable inventor based in Nürnberg, Germany. He has made significant contributions to the field of immunology through his innovative research and patents. His work focuses on novel semaphorins, which play a crucial role in the immune system.
Latest Patents
Armin Ensser holds a patent for "Human semaphorin L (H-SemaL) and corresponding semaphorins in other species." This invention relates to novel semaphorins characterized by a unique domain structure and their derivatives. The patent also includes nucleic acids (DNA, RNA, cDNA) that code for these semaphorins and their derivatives. The semaphorins described in this patent possess a previously undisclosed domain structure and exhibit a biochemical function in the immune system, specifically as immunomodulating semaphorins. These novel semaphorins are classified as type L semaphorins (SemaL) and include an N-terminal signal peptide, a characteristic Sema domain, and an immunoglobulin-like domain in the C-terminal region, along with a potential transmembrane hydrophobic domain.
Career Highlights
Armin Ensser is currently associated with Sanofi-Aventis Deutschland GmbH, where he continues to advance his research in immunology. His work has garnered attention for its potential applications in therapeutic interventions.
Collaborations
Armin Ensser has collaborated with Bernhard W. Fleckenstein, contributing to the advancement of knowledge in their field.
Conclusion
Armin Ensser's innovative work on semaphorins represents a significant advancement in immunology, with the potential to impact therapeutic strategies in the future. His contributions continue to shape the understanding of immune system functions.